Leeds Teaching Hospitals NHS Trust (LTHT)

grid.415967.8

CQC Registered Health or/and Social Care provider

Hormone receptor-positive, HER2-negative breast cancer is the most common type of breast cancer. While many people are diagnosed at an early stage, some develop advanced disease (metastatic breast cancer), either from the start or after initial treatment. Treatment options have improved in recent years, especially with the introduction of targeted therapies and drug combinations, which can now help many people live longer and with better quality of life. This study looked at how people with advanced breast cancer are being treated across different cancer centres in Europe. By using key clinical information from patient records, the study aimed to understand treatment choices, how care differs between centres, and whether treatment guidelines are being followed. It also looked at how newer tests and treatments are being used in everyday practice.

This study uses real-world data from across Europe to better understand how advanced breast cancer is treated and how care could be improved. By comparing treatment and outcomes between centres, it helps identify where care is working well and where changes could help patients. The findings will support better use of new tests and treatments and help make sure all patients receive high-quality care based on the latest evidence and guidelines.

01/03/2023

Yes

Federated analysis on OMOP database - no direct access to patient-level data